Relapsed/Refractory Hodgkin Lymphoma

Mar 1, 2017 by in HEMATOLOGY Comments Off on Relapsed/Refractory Hodgkin Lymphoma

For relapsed-refractory Hodgkin Lymphoma, standard therapy consists of salvage chemotherapy followed by autologous stem cell transplantation. Adverse risk factors at relapse include response duration less than 12 months, advanced stage,…

read more

Customized Targeted Therapy in Hodgkin Lymphoma

Mar 1, 2017 by in HEMATOLOGY Comments Off on Customized Targeted Therapy in Hodgkin Lymphoma

Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical…

read more

FDG-PET Response–adapted Therapy

Mar 1, 2017 by in HEMATOLOGY Comments Off on FDG-PET Response–adapted Therapy

Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is the most accurate tool for staging, treatment monitoring, and response evaluation in Hodgkin lymphoma (HL). Early determination of treatment sensitivity by…

read more

Combination Chemoradiotherapy in Early Hodgkin Lymphoma

Mar 1, 2017 by in HEMATOLOGY Comments Off on Combination Chemoradiotherapy in Early Hodgkin Lymphoma

Combination chemoradiotherapy achieves excellent results for the treatment of localized Hodgkin lymphoma. However, late toxic effects occur, mostly related to the radiotherapy administered after the standard adriamycin, bleomycin, vinblastine, and…

read more
Get Clinical Tree app for offline access